Author

A. C. Leung

Observed name: ACF Leung

Institutions: Université Libre de Bruxelles, Mayo Clinic, Nektar Therapeutics (United States), Mayo Clinic in Florida

Observed institutions: Université Libre de Bruxelles, Mayo Clinic, Nektar Therapeutics (United States), Mayo Clinic in Florida

OpenAlex ID: A5087412708

The role of NKTR-102 in women with platinum resistant/refractory ovarian cancer and failure on pegylated liposomal doxorubicin (PLD).

2011 · A. A. Garcia, I. B. Vergote, et al. · Journal of Clinical Oncology · 6

OT3-01-07: The BEACON Study (BrEAst Cancer Outcomes with NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (MBC) Previously Treated with an Anthracycline, a Taxane, and Capecitabine (ATC).

2011 · A Awada, ACF Leung, et al. · Cancer Research · 2

Works count: 2

Citation count: 8

H-index: 2

I10-index: